论文部分内容阅读
利用脂质体包被IL-2理论上能达到IL-2用量小、副作用少、疗效提高等效果.们前期应用脂质体IL-2联合CD3AK细胞治疗鼠肝黑色素转移瘤,取得了满意的实验结果.在此基础上,再探讨脂质体IL-2联合TIL、CY抗鼠肝癌的作用,旨在证明脂质体IL-2的优越性.1 材料与方法制备鼠H22肝癌皮下荷瘤模型,然后采用机械、酶消化和不连续密度梯度离心分离获得TIL,体外掺入rIL-2(1000U/ml)后培养、扩增.参照Konno及我所建立的制备脂质体方法制备复层大囊泡rIL-2脂质体(MLV-rIL-2).取昆明鼠40只随机分4组(即对照组、TIL+CY组、TIL+CY+rIL-2组、TIL+CY+MLV-rIL-2组),每组10只进行体内治疗.后3组治疗开始前3天均用环磷酰胺(CY)腹腔注射,每日1次CY50mg/kg,然后尾静脉注射TIL,每次每只
Liposome-encapsulated IL-2 can theoretically achieve the effects of small amount of IL-2, less side effects, and improved efficacy. We have previously used liposome IL-2 in combination with CD3AK cells to treat mouse liver melanoma metastases and achieved satisfactory results. Experimental results. Based on this, the role of liposome IL-2 in combination with TIL and CY anti-rat liver cancer was further explored in order to prove the superiority of liposome IL-2.1 Materials and Methods Preparation of subcutaneous tumors of rat H22 liver cancer The model was then mechanically, enzymatically digested, and discontinuously density-graded by centrifugation to obtain TIL. After in vitro incorporation of rIL-2 (1000 U/ml), they were cultured and expanded. The composite layer was prepared by the method of preparing liposomes established by Konno and I. Large vesicle rIL-2 liposome (MLV-rIL-2). 40 Kunming mice were randomly divided into 4 groups (ie, control group, TIL+CY group, TIL+CY+rIL-2 group, TIL+CY+MLV -rIL-2 group), 10 in each group were treated in vivo. After 3 groups of treatment, 3 groups were injected with cyclophosphamide (CY) intraperitoneally 3 days before, CY 50mg/kg once a day, and then TIL was injected into the tail vein. Each